Which management step is commonly used for moderate to severe immune-related adverse events from checkpoint inhibitors?

• A. Steroids
• B. Antibiotics
• C. Increased chemotherapy dosing
• D. IV fluids only

Answer: (A)

Immune-related adverse events from checkpoint inhibitors are inflammatory reactions driven by an overactive immune system, so the treatment goal is to suppress that immune attack. For moderate to severe irAEs, the best and standard first step is systemic corticosteroids. They rapidly reduce immune-mediated inflammation across affected organs, helping symptoms improve and preventing progression. The typical approach is to start high-dose steroids (for example, prednisone about 1 mg/kg/day or an equivalent dose of methylprednisolone) and hold the immunotherapy until there is meaningful improvement, then taper the steroids over several weeks as symptoms resolve. If symptoms persist or recur during tapering, additional immunosuppressive therapies may be used depending on the organ involved.

Antibiotics are reserved for confirmed or strongly suspected infections, not for treating irAEs. Increasing chemotherapy dosing would worsen toxicity and does not address the inflammatory process. IV fluids alone won’t control immune-mediated inflammation.